Clinical trials: Postmenopausal Women With Osteoporosis
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Open Label Extension Study of PREOS
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human…
- Trial name
- OLES (NCT00172133)
- Testing
- ALX1-11 (drug)
- Where
- 132 sites in United States, Argentina and 6 more
- Volunteers
- 1,683 people
- Sponsor
- Shire
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.
- Trial name
- NCT00542425
- Testing
- teriparatide, BA058 20 µg, BA058 40 µg
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Radius Health, Inc.
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis
Differentiated Thyroid Cancer, Osteoporosis
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis.
- Trial name
- NCT02304757
- Testing
- 99Tc-MDP, Fosamax
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Osteoporosis, Postmenopausal
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed…
- Trial name
- NCT00035256
- Testing
- teriparatide, raloxifene HCl
- Where
- 5 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis, Vertebral Fracture
How Vertebral Fractures Effect Balance In Postmenopausal Women
Osteoporosis is defined as low bone mineral density caused by altered bone microstructure, ultimately predisposing patients to fragility fractures.
- Conditions
- Postmenopausal Osteoporosis, Vertebral Fracture, Fracture of Vertebra, Fall
- Trial name
- NCT06502301
- Testing
- Cross-sectional study
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people
- Sponsor
- Istanbul University - Cerrahpasa
Postmenopausal Osteoporosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
- Trial name
- NCT00676312
- Testing
- PTH134
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
Quality of Life in Postmenopausal Women With Osteoporosis
The researchers will evaluate the effectiveness of a complex intervention composed of multiple actions targeting primary care healthcare workers and postmenopausal women with osteoporosis by means of a quasi-experimental design…
- Trial name
- NCT03970902
- Testing
- Integrated Osteoporosis Care, Care As Usual
- Where
- Belgium
- Volunteers
- 239 people
- Sponsor
- University Ghent
Osteoporosis, Multiple Myeloma
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in…
- Trial name
- NCT05775094
- Testing
- Romosozumab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoporosis, Osteopenia
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.
- Trial name
- NCT01604057
- Testing
- ZT-034 Low Dose Nasal Spray, ZT-034 Mid Dose Nasal Spray, ZT-034 High Dose Nasal Spray
- Volunteers
- 130 people
- Sponsor
- Azelon Pharmaceuticals
Osteoporosis, Postmenopausal
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in…
- Trial name
- ALVOBOND (NCT05395091)
- Testing
- AVT03, Denosumab
- Where
- 34 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 532 people
- Sponsor
- Alvotech Swiss AG
Osteoporosis, Postmenopausal, Osteopenia
High-Intensity Laser Therapy and Physiotherapy for Bone Health in Postmenopausal Women: A Randomized Trial
The goal of this clinical trial is to learn if adding high-intensity laser therapy (HILT) to a physiotherapy programme helps bone health in women after menopause who have low bone density (osteopenia or osteoporosis).
- Trial name
- NCT07734922
- Testing
- High-Intensity Laser Therapy, Standardised Physiotherapy Programme
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Osteoporosis, Postmenopausal, Osteopenia
Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)
The purpose of this study is to evaluate the effect of alfacalcidol 1 µg daily on the number of fallers in postmenopausal, alendronate-treated, osteopenic or osteoporotic women.
- Conditions
- Osteoporosis, Postmenopausal, Osteopenia, Falls
- Trial name
- NCT00168909
- Testing
- alfacalcidol
- Where
- 2 sites in Germany
- Volunteers
- 282 people
- Sponsor
- Charite University, Berlin, Germany
Postmenopausal
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized…
- Trial name
- NCT05352516
- Testing
- HLX14, Prolia®
- Where
- 38 sites in China
- Volunteers
- 514 people
- Sponsor
- Shanghai Henlius Biotech
Postmenopausal Osteoporosis
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
The main objective of this observational study was to describe medication-taking behavior of patients treated with denosumab for postmenopausal osteoporosis (PMO) at 12 and 24 months.
- Trial name
- NCT01668589
- Where
- 144 sites in Austria, Belgium and 2 more
- Volunteers
- 1,501 people
- Sponsor
- Amgen
Osteoporosis, Osteopenia
The Effect of Exercise in Postmenopausal Women with Low Bone Density
This clinical trial aims to evaluate the effects of a 12 month gym- and home-based exercise program on bone density and falls risk factors in postmenopausal women with low bone density.
- Trial name
- NCT00643331
- Testing
- Exercise
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Postmenopausal Osteoporosis
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
The aim of this study is to directly compare the bone forming effects of 20 microg/day of teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric variables and biochemical bone formation markers…
- Trial name
- NCT00239629
- Testing
- Teriparatide, Strontium ranelate, Transiliac bone biopsy
- Where
- 11 sites in Czechia, Germany and 4 more
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company